Clinical Trial Update: Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update evaluating the combination of necitumumab, trastuzumab, and osimertinib for refractory EGFR-mutated stage IV non-small cell lung…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Egfr-mutated Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Necitumumab (necitumumab)
• Osimertinib (osimertinib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING